• TriGemX Bio and TCGX Acquisition confidentially submitted a draft Form S-4 registration statement for their previously announced combination.
• The deal would take TriGemX Bio public on Nasdaq under ticker TGEM, with closing expected in the first quarter of 2027.
• Completion remains subject to shareholder approval, registration statement effectiveness and Nasdaq listing approval.
• TriGemX Bio’s migraine treatment elismetrep is in Phase 3 trials, with initial results expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TCGX Acquisition Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102177653) on November 02, 2026, and is solely responsible for the information contained therein.